In therapy for type 2 diabetes, the addition of insulin is most effective when combined with which oral agent?

In therapy for type 2 diabetes, the addition of insulin is most effective when combined with which oral agent?

• A. Alpha-glucosidase inhibitors
• B. Insulin secretagogues
• C. Metformin
• D. SGLT2 inhibitors

Answer: (C)

Metformin paired with insulin is most effective because it tackles a different aspect of glucose control than insulin does. Metformin mainly reduces hepatic glucose production and improves insulin sensitivity in muscle and fat. This lowers fasting and overall glucose levels without adding risk of hypoglycemia on its own, and it tends to cause little or even modest weight loss. When used with insulin, metformin can lessen the required insulin dose and help prevent insulin-associated weight gain, providing a complementary mechanism to insulin’s effect on glucose disposal. Other options don’t offer the same broad, synergistic benefits. Alpha-glucosidase inhibitors mainly blunt postprandial glucose with modest overall impact and can cause GI side effects. Insulin secretagogues increase insulin secretion but raise the risk of hypoglycemia and can promote weight gain when used with insulin. SGLT2 inhibitors promote glucose loss in the urine and have advantages like weight loss and CV/renal benefits, but their effect on fasting glucose via hepatic output isn’t as strong as metformin’s, and they don’t address insulin resistance as directly.

Metformin paired with insulin is most effective because it tackles a different aspect of glucose control than insulin does. Metformin mainly reduces hepatic glucose production and improves insulin sensitivity in muscle and fat. This lowers fasting and overall glucose levels without adding risk of hypoglycemia on its own, and it tends to cause little or even modest weight loss. When used with insulin, metformin can lessen the required insulin dose and help prevent insulin-associated weight gain, providing a complementary mechanism to insulin’s effect on glucose disposal.

Other options don’t offer the same broad, synergistic benefits. Alpha-glucosidase inhibitors mainly blunt postprandial glucose with modest overall impact and can cause GI side effects. Insulin secretagogues increase insulin secretion but raise the risk of hypoglycemia and can promote weight gain when used with insulin. SGLT2 inhibitors promote glucose loss in the urine and have advantages like weight loss and CV/renal benefits, but their effect on fasting glucose via hepatic output isn’t as strong as metformin’s, and they don’t address insulin resistance as directly.